XML 74 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition of Molecular Insight Pharmaceuticals, Inc (Tables)
 6 Months Ended
Jun. 30, 2013
Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]  
Schedule Purchase Price Allocation [Table Text Block]
 
 
Amount
 
Consideration:
 
 
Progenics common stock consideration
 
$
11,265
 
Contingent consideration (pursuant to future milestone obligations)
  
15,900
 
Total consideration
  
27,165
 
 
    
Tangible assets acquired and liabilities assumed:
    
Cash and cash equivalents
  
1,888
 
Accounts receivable
  
56
 
Other current assets
  
529
 
Fixed assets
  
249
 
Accounts payable, accrued expenses and deferred revenue - current
  
(2,876
)
Deferred tax liability – long term
  
(12,683
)
Total tangible assets acquired and liabilities assumed
  
(12,837
)
 
    
Intangible assets - in process research and development
  
32,300
 
Total tangible and intangible assets acquired and liabilities assumed
  
19,463
 
 
    
Goodwill
 
$
7,702
 
Business Acquisition, Pro Forma Information
 
 
Three Months Ended
June 30,
  
Six Months Ended
June 30,
 
 
 
2013
  
2012
  
2013
  
2012
 
Revenues
 
$
1,801
  
$
1,836
  
$
4,032
  
$
4,148
 
Net loss
  
(12,223
)
  
(17,740
)
  
(24,685
)
  
(38,011
)
Basic and diluted loss per share
  
(0.24
)
  
(0.46
)
  
(0.49
)
  
(0.99
)